相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)
Borghaei
JOURNAL OF CLINICAL ONCOLOGY (2021)
Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer
Jodi Gray et al.
MEDICAL DECISION MAKING (2021)
Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data
Mohammad A. Chaudhary et al.
JOURNAL OF MEDICAL ECONOMICS (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mixture Cure Models in Oncology: A Tutorial and Practical Guidance
Federico Felizzi et al.
PHARMACOECONOMICS-OPEN (2021)
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Ben Rothwell et al.
PHARMACOECONOMICS-OPEN (2021)
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J. Motzer et al.
CANCER (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Mario J. N. M. Ouwens et al.
PHARMACOECONOMICS (2019)
Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
Vera Damuzzo et al.
FRONTIERS IN ONCOLOGY (2019)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott J. Antonia et al.
LANCET ONCOLOGY (2019)
An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data
Adrian Vickers
MEDICAL DECISION MAKING (2019)
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement et al.
VALUE IN HEALTH (2019)
Extrapolation of Survival Curves from Cancer Trials Using External Information
Patricia Guyot et al.
MEDICAL DECISION MAKING (2017)
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
Christopher Jackson et al.
MEDICAL DECISION MAKING (2017)
Stan: A Probabilistic Programming Language
Bob Carpenter et al.
JOURNAL OF STATISTICAL SOFTWARE (2017)
Accounting for Cured Patients in Cost-Effectiveness Analysis
Megan Othus et al.
VALUE IN HEALTH (2017)
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
Ron Goeree et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Patrick Royston et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
P Royston et al.
STATISTICS IN MEDICINE (2002)
分享论文
